August 1, 2007 — Daxor, a medical instrumentation and biotechnology company, announced the publication of the article "Measurement of Blood Volume at Bedside: New Era in Critical Care Medicine" in the Internet Journal of Emergency and Intensive Care Medicine (2007; Volume 10, Number 1).
Bobbak Vahid M.D., of the Department of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, is cited as the main author. The Internet Journal of Emergency and Intensive Care Medicine is a peer-reviewed on-line journal.
The study article discusses that, "Accurate assessment of volume status of the critically care ill patient in the intensive care unit is a challenging task facing intensivists each day." Additionally, surrogate measurements compared to a measured blood volume with Daxor's Blood Volume Analyzer has shown to be accurate "less than 50%."
Blood volume estimates by extremely invasive procedures, various physical signs and symptoms and surrogate measurements are often the standard of care because of the past inability of clinicians to have access to an accurate, repeatable, FDA approved diagnostic instrument. With the introduction of Daxor's BVA-100, studies have shown to influence changes in treatment decisions 20% to 35% of patients.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit.
For more information: www.Daxor.com